nodes	percent_of_prediction	percent_of_DWPC	metapath
Methotrexate—bone cancer—sarcoma	0.117	0.237	CtDrD
Methotrexate—muscle cancer—sarcoma	0.104	0.209	CtDrD
Methotrexate—testicular cancer—sarcoma	0.0973	0.196	CtDrD
Methotrexate—germ cell cancer—sarcoma	0.0932	0.188	CtDrD
Methotrexate—PGD—Dacarbazine—sarcoma	0.0878	0.256	CbGbCtD
Methotrexate—lung cancer—sarcoma	0.0837	0.169	CtDrD
Methotrexate—ABCC10—Vincristine—sarcoma	0.0269	0.0786	CbGbCtD
Methotrexate—ABCC10—Etoposide—sarcoma	0.0247	0.072	CbGbCtD
Methotrexate—ABCC3—Vincristine—sarcoma	0.0169	0.0494	CbGbCtD
Methotrexate—ABCC1—Dactinomycin—sarcoma	0.0169	0.0493	CbGbCtD
Methotrexate—ABCC10—Doxorubicin—sarcoma	0.0168	0.0491	CbGbCtD
Methotrexate—ABCC3—Etoposide—sarcoma	0.0155	0.0453	CbGbCtD
Methotrexate—ABCC1—Mitoxantrone—sarcoma	0.0151	0.0441	CbGbCtD
Methotrexate—ABCC1—Epirubicin—sarcoma	0.0122	0.0357	CbGbCtD
Methotrexate—ABCG2—Dactinomycin—sarcoma	0.0113	0.033	CbGbCtD
Methotrexate—ABCC3—Doxorubicin—sarcoma	0.0106	0.0309	CbGbCtD
Methotrexate—ABCC1—Vincristine—sarcoma	0.0104	0.0303	CbGbCtD
Methotrexate—ABCG2—Mitoxantrone—sarcoma	0.0101	0.0295	CbGbCtD
Methotrexate—ABCC1—Etoposide—sarcoma	0.00953	0.0278	CbGbCtD
Methotrexate—ABCC2—Vincristine—sarcoma	0.0077	0.0225	CbGbCtD
Methotrexate—ABCC2—Etoposide—sarcoma	0.00705	0.0206	CbGbCtD
Methotrexate—ABCG2—Vincristine—sarcoma	0.00696	0.0203	CbGbCtD
Methotrexate—ABCC1—Doxorubicin—sarcoma	0.0065	0.019	CbGbCtD
Methotrexate—ABCG2—Etoposide—sarcoma	0.00638	0.0186	CbGbCtD
Methotrexate—ABCC2—Doxorubicin—sarcoma	0.00481	0.014	CbGbCtD
Methotrexate—ABCG2—Doxorubicin—sarcoma	0.00435	0.0127	CbGbCtD
Methotrexate—ABCB1—Dactinomycin—sarcoma	0.00407	0.0119	CbGbCtD
Methotrexate—ABCB1—Mitoxantrone—sarcoma	0.00365	0.0106	CbGbCtD
Methotrexate—ATIC—pes—sarcoma	0.0031	0.0627	CbGeAlD
Methotrexate—ABCB1—Vincristine—sarcoma	0.00251	0.00732	CbGbCtD
Methotrexate—ABCB1—Etoposide—sarcoma	0.0023	0.00671	CbGbCtD
Methotrexate—ATIC—leg—sarcoma	0.00158	0.0319	CbGeAlD
Methotrexate—ABCB1—Doxorubicin—sarcoma	0.00157	0.00458	CbGbCtD
Methotrexate—ATIC—forelimb—sarcoma	0.00157	0.0317	CbGeAlD
Methotrexate—ATIC—hindlimb—sarcoma	0.00141	0.0285	CbGeAlD
Methotrexate—ATIC—appendage—sarcoma	0.00121	0.0245	CbGeAlD
Methotrexate—FOLR1—mammary gland—sarcoma	0.00104	0.0211	CbGeAlD
Methotrexate—ABCC11—mammary gland—sarcoma	0.000998	0.0202	CbGeAlD
Methotrexate—SLC19A1—mammary gland—sarcoma	0.000913	0.0185	CbGeAlD
Methotrexate—ABCC11—embryo—sarcoma	0.000681	0.0138	CbGeAlD
Methotrexate—FOLR1—seminal vesicle—sarcoma	0.000667	0.0135	CbGeAlD
Methotrexate—FOLR1—hematopoietic system—sarcoma	0.000634	0.0128	CbGeAlD
Methotrexate—ATIC—mammary gland—sarcoma	0.000588	0.0119	CbGeAlD
Methotrexate—SLC19A1—hematopoietic system—sarcoma	0.000556	0.0113	CbGeAlD
Methotrexate—GGH—myometrium—sarcoma	0.000491	0.00994	CbGeAlD
Methotrexate—FOLR1—uterus—sarcoma	0.000479	0.0097	CbGeAlD
Methotrexate—SLC46A1—seminal vesicle—sarcoma	0.000451	0.00912	CbGeAlD
Methotrexate—FOLR1—lymphoid tissue—sarcoma	0.000446	0.00904	CbGeAlD
Methotrexate—GGH—seminal vesicle—sarcoma	0.000443	0.00898	CbGeAlD
Methotrexate—MTHFR—mammary gland—sarcoma	0.000437	0.00885	CbGeAlD
Methotrexate—FPGS—myometrium—sarcoma	0.000431	0.00874	CbGeAlD
Methotrexate—SLC46A1—hematopoietic system—sarcoma	0.000428	0.00867	CbGeAlD
Methotrexate—ATIC—embryo—sarcoma	0.000401	0.00813	CbGeAlD
Methotrexate—TYMS—Vinorelbine—Vincristine—sarcoma	0.000398	0.372	CbGdCrCtD
Methotrexate—TYMS—Podofilox—Etoposide—sarcoma	0.000398	0.372	CbGdCrCtD
Methotrexate—SLCO4C1—seminal vesicle—sarcoma	0.000393	0.00796	CbGeAlD
Methotrexate—SLC19A1—lymphoid tissue—sarcoma	0.000392	0.00793	CbGeAlD
Methotrexate—FPGS—seminal vesicle—sarcoma	0.00039	0.00789	CbGeAlD
Methotrexate—PGD—mammary gland—sarcoma	0.00038	0.00769	CbGeAlD
Methotrexate—GGH—smooth muscle tissue—sarcoma	0.000371	0.00751	CbGeAlD
Methotrexate—FPGS—hematopoietic system—sarcoma	0.00037	0.0075	CbGeAlD
Methotrexate—GGH—skin of body—sarcoma	0.000366	0.00742	CbGeAlD
Methotrexate—ATIC—hematopoietic system—sarcoma	0.000358	0.00725	CbGeAlD
Methotrexate—FPGS—connective tissue—sarcoma	0.000357	0.00722	CbGeAlD
Methotrexate—ATIC—connective tissue—sarcoma	0.000345	0.00699	CbGeAlD
Methotrexate—SLCO1B1—mammary gland—sarcoma	0.000345	0.00698	CbGeAlD
Methotrexate—ABCC11—testis—sarcoma	0.000333	0.00675	CbGeAlD
Methotrexate—FPGS—skin of body—sarcoma	0.000322	0.00652	CbGeAlD
Methotrexate—GGH—uterus—sarcoma	0.000318	0.00644	CbGeAlD
Methotrexate—ATIC—smooth muscle tissue—sarcoma	0.000316	0.00639	CbGeAlD
Methotrexate—ABCC11—liver—sarcoma	0.000315	0.00638	CbGeAlD
Methotrexate—ATIC—skin of body—sarcoma	0.000312	0.00631	CbGeAlD
Methotrexate—SLCO3A1—myometrium—sarcoma	0.000305	0.00618	CbGeAlD
Methotrexate—SLC19A1—testis—sarcoma	0.000305	0.00617	CbGeAlD
Methotrexate—SLC46A1—lymphoid tissue—sarcoma	0.000302	0.00611	CbGeAlD
Methotrexate—SLC19A1—liver—sarcoma	0.000288	0.00583	CbGeAlD
Methotrexate—SLC46A1—tendon—sarcoma	0.000284	0.00574	CbGeAlD
Methotrexate—FPGS—cardiac atrium—sarcoma	0.000281	0.0057	CbGeAlD
Methotrexate—DHFR—myometrium—sarcoma	0.00028	0.00567	CbGeAlD
Methotrexate—ALB—mammary gland—sarcoma	0.000279	0.00565	CbGeAlD
Methotrexate—GGH—tendon—sarcoma	0.000279	0.00565	CbGeAlD
Methotrexate—SLCO3A1—seminal vesicle—sarcoma	0.000276	0.00558	CbGeAlD
Methotrexate—TYMS—Vinblastine—Vincristine—sarcoma	0.000274	0.256	CbGdCrCtD
Methotrexate—ATIC—uterus—sarcoma	0.000271	0.00548	CbGeAlD
Methotrexate—GGH—bone marrow—sarcoma	0.00027	0.00547	CbGeAlD
Methotrexate—DHFR—embryo—sarcoma	0.00027	0.00546	CbGeAlD
Methotrexate—PGD—myometrium—sarcoma	0.000269	0.00545	CbGeAlD
Methotrexate—MTHFR—hematopoietic system—sarcoma	0.000266	0.00539	CbGeAlD
Methotrexate—FPGS—lymphoid tissue—sarcoma	0.000261	0.00528	CbGeAlD
Methotrexate—DHFR—seminal vesicle—sarcoma	0.000253	0.00513	CbGeAlD
Methotrexate—ATIC—lymphoid tissue—sarcoma	0.000252	0.00511	CbGeAlD
Methotrexate—FPGS—tendon—sarcoma	0.000245	0.00496	CbGeAlD
Methotrexate—PGD—seminal vesicle—sarcoma	0.000243	0.00493	CbGeAlD
Methotrexate—TYMS—hematopoietic system—sarcoma	0.000243	0.00492	CbGeAlD
Methotrexate—DHFR—hematopoietic system—sarcoma	0.000241	0.00487	CbGeAlD
Methotrexate—SLCO4C1—bone marrow—sarcoma	0.00024	0.00485	CbGeAlD
Methotrexate—AOX1—myometrium—sarcoma	0.000237	0.0048	CbGeAlD
Methotrexate—SLC46A1—testis—sarcoma	0.000235	0.00475	CbGeAlD
Methotrexate—TYMS—connective tissue—sarcoma	0.000234	0.00474	CbGeAlD
Methotrexate—DHFR—connective tissue—sarcoma	0.000232	0.00469	CbGeAlD
Methotrexate—PGD—hematopoietic system—sarcoma	0.000231	0.00468	CbGeAlD
Methotrexate—ABCC10—myometrium—sarcoma	0.000231	0.00468	CbGeAlD
Methotrexate—GGH—testis—sarcoma	0.000231	0.00468	CbGeAlD
Methotrexate—PGD—connective tissue—sarcoma	0.000223	0.00451	CbGeAlD
Methotrexate—SLC46A1—liver—sarcoma	0.000222	0.00449	CbGeAlD
Methotrexate—SLC19A1—lymph node—sarcoma	0.000221	0.00447	CbGeAlD
Methotrexate—GGH—liver—sarcoma	0.000218	0.00442	CbGeAlD
Methotrexate—SLC16A1—hematopoietic system—sarcoma	0.000216	0.00437	CbGeAlD
Methotrexate—AOX1—seminal vesicle—sarcoma	0.000214	0.00434	CbGeAlD
Methotrexate—TYMS—smooth muscle tissue—sarcoma	0.000214	0.00433	CbGeAlD
Methotrexate—TYMS—skin of body—sarcoma	0.000211	0.00428	CbGeAlD
Methotrexate—SLCO1B1—hematopoietic system—sarcoma	0.00021	0.00425	CbGeAlD
Methotrexate—ABCC10—seminal vesicle—sarcoma	0.000209	0.00423	CbGeAlD
Methotrexate—PGD—smooth muscle tissue—sarcoma	0.000204	0.00412	CbGeAlD
Methotrexate—FPGS—testis—sarcoma	0.000203	0.00411	CbGeAlD
Methotrexate—PGD—skin of body—sarcoma	0.000201	0.00407	CbGeAlD
Methotrexate—ABCC3—hematopoietic system—sarcoma	0.000199	0.00404	CbGeAlD
Methotrexate—SLCO3A1—cardiac atrium—sarcoma	0.000199	0.00403	CbGeAlD
Methotrexate—ABCC10—hematopoietic system—sarcoma	0.000198	0.00402	CbGeAlD
Methotrexate—ATIC—testis—sarcoma	0.000196	0.00398	CbGeAlD
Methotrexate—SLCO4C1—liver—sarcoma	0.000194	0.00392	CbGeAlD
Methotrexate—FPGS—liver—sarcoma	0.000192	0.00389	CbGeAlD
Methotrexate—SLCO1B3—liver—sarcoma	0.000188	0.00381	CbGeAlD
Methotrexate—MTHFR—lymphoid tissue—sarcoma	0.000187	0.0038	CbGeAlD
Methotrexate—ATIC—liver—sarcoma	0.000186	0.00376	CbGeAlD
Methotrexate—DHFR—cardiac atrium—sarcoma	0.000183	0.0037	CbGeAlD
Methotrexate—DHFR—uterus—sarcoma	0.000182	0.00368	CbGeAlD
Methotrexate—PGD—cardiac atrium—sarcoma	0.000176	0.00356	CbGeAlD
Methotrexate—PGD—uterus—sarcoma	0.000175	0.00354	CbGeAlD
Methotrexate—SLCO3A1—tendon—sarcoma	0.000173	0.00351	CbGeAlD
Methotrexate—TYMS—lymphoid tissue—sarcoma	0.000171	0.00346	CbGeAlD
Methotrexate—SLCO1A2—hematopoietic system—sarcoma	0.000171	0.00346	CbGeAlD
Methotrexate—SLC46A1—lymph node—sarcoma	0.00017	0.00344	CbGeAlD
Methotrexate—DHFR—lymphoid tissue—sarcoma	0.000169	0.00343	CbGeAlD
Methotrexate—GGH—lymph node—sarcoma	0.000167	0.00339	CbGeAlD
Methotrexate—ABCC4—hematopoietic system—sarcoma	0.000165	0.00333	CbGeAlD
Methotrexate—SLC16A1—cardiac atrium—sarcoma	0.000164	0.00332	CbGeAlD
Methotrexate—ABCC1—myometrium—sarcoma	0.000163	0.00331	CbGeAlD
Methotrexate—SLCO1C1—testis—sarcoma	0.000163	0.00331	CbGeAlD
Methotrexate—SLC22A8—hematopoietic system—sarcoma	0.000163	0.0033	CbGeAlD
Methotrexate—SLC16A1—uterus—sarcoma	0.000163	0.0033	CbGeAlD
Methotrexate—PGD—lymphoid tissue—sarcoma	0.000163	0.0033	CbGeAlD
Methotrexate—TYMS—tendon—sarcoma	0.000161	0.00326	CbGeAlD
Methotrexate—DHFR—tendon—sarcoma	0.000159	0.00322	CbGeAlD
Methotrexate—TYMS—bone marrow—sarcoma	0.000156	0.00315	CbGeAlD
Methotrexate—SLC22A7—testis—sarcoma	0.000155	0.00313	CbGeAlD
Methotrexate—AOX1—cardiac atrium—sarcoma	0.000155	0.00313	CbGeAlD
Methotrexate—DHFR—bone marrow—sarcoma	0.000154	0.00312	CbGeAlD
Methotrexate—AOX1—uterus—sarcoma	0.000154	0.00312	CbGeAlD
Methotrexate—PGD—tendon—sarcoma	0.000153	0.0031	CbGeAlD
Methotrexate—ABCC10—cardiac atrium—sarcoma	0.000151	0.00305	CbGeAlD
Methotrexate—SLC22A11—liver—sarcoma	0.00015	0.00304	CbGeAlD
Methotrexate—ABCC10—uterus—sarcoma	0.00015	0.00303	CbGeAlD
Methotrexate—PGD—bone marrow—sarcoma	0.000148	0.003	CbGeAlD
Methotrexate—ABCC1—seminal vesicle—sarcoma	0.000148	0.00299	CbGeAlD
Methotrexate—FPGS—lymph node—sarcoma	0.000147	0.00298	CbGeAlD
Methotrexate—SLC22A7—liver—sarcoma	0.000146	0.00296	CbGeAlD
Methotrexate—MTHFR—testis—sarcoma	0.000146	0.00295	CbGeAlD
Methotrexate—SLCO3A1—testis—sarcoma	0.000144	0.00291	CbGeAlD
Methotrexate—SLC16A1—tendon—sarcoma	0.000143	0.00289	CbGeAlD
Methotrexate—ATIC—lymph node—sarcoma	0.000142	0.00288	CbGeAlD
Methotrexate—ABCC10—lymphoid tissue—sarcoma	0.00014	0.00283	CbGeAlD
Methotrexate—MTHFR—liver—sarcoma	0.000138	0.00279	CbGeAlD
Methotrexate—SLCO3A1—liver—sarcoma	0.000136	0.00275	CbGeAlD
Methotrexate—ABCG2—myometrium—sarcoma	0.000135	0.00274	CbGeAlD
Methotrexate—AOX1—tendon—sarcoma	0.000135	0.00273	CbGeAlD
Methotrexate—TYMS—testis—sarcoma	0.000133	0.0027	CbGeAlD
Methotrexate—DHFR—testis—sarcoma	0.000132	0.00267	CbGeAlD
Methotrexate—ABCC10—tendon—sarcoma	0.000131	0.00266	CbGeAlD
Methotrexate—ABCC10—bone marrow—sarcoma	0.000127	0.00257	CbGeAlD
Methotrexate—PGD—testis—sarcoma	0.000127	0.00257	CbGeAlD
Methotrexate—TYMS—liver—sarcoma	0.000126	0.00255	CbGeAlD
Methotrexate—DHFR—liver—sarcoma	0.000125	0.00252	CbGeAlD
Methotrexate—ABCC4—uterus—sarcoma	0.000124	0.00252	CbGeAlD
Methotrexate—ABCG2—seminal vesicle—sarcoma	0.000122	0.00247	CbGeAlD
Methotrexate—PGD—liver—sarcoma	0.00012	0.00243	CbGeAlD
Methotrexate—SLC16A1—testis—sarcoma	0.000118	0.0024	CbGeAlD
Methotrexate—SLCO1C1—lymph node—sarcoma	0.000118	0.0024	CbGeAlD
Methotrexate—SLC16A1—liver—sarcoma	0.000112	0.00227	CbGeAlD
Methotrexate—AOX1—testis—sarcoma	0.000112	0.00226	CbGeAlD
Methotrexate—ABCC3—testis—sarcoma	0.000109	0.00221	CbGeAlD
Methotrexate—ABCC4—tendon—sarcoma	0.000109	0.0022	CbGeAlD
Methotrexate—SLCO1B1—liver—sarcoma	0.000109	0.0022	CbGeAlD
Methotrexate—ABCC10—testis—sarcoma	0.000109	0.0022	CbGeAlD
Methotrexate—ABCC1—cardiac atrium—sarcoma	0.000107	0.00216	CbGeAlD
Methotrexate—ABCC1—uterus—sarcoma	0.000106	0.00215	CbGeAlD
Methotrexate—MTHFR—lymph node—sarcoma	0.000106	0.00214	CbGeAlD
Methotrexate—AOX1—liver—sarcoma	0.000106	0.00214	CbGeAlD
Methotrexate—ABCC4—bone marrow—sarcoma	0.000105	0.00214	CbGeAlD
Methotrexate—ABCC2—tendon—sarcoma	0.000105	0.00213	CbGeAlD
Methotrexate—SLCO3A1—lymph node—sarcoma	0.000104	0.00211	CbGeAlD
Methotrexate—ABCC3—liver—sarcoma	0.000103	0.00209	CbGeAlD
Methotrexate—ABCC10—liver—sarcoma	0.000103	0.00208	CbGeAlD
Methotrexate—TYMS—lymph node—sarcoma	9.65e-05	0.00195	CbGeAlD
Methotrexate—DHFR—lymph node—sarcoma	9.56e-05	0.00194	CbGeAlD
Methotrexate—SLCO1A2—testis—sarcoma	9.37e-05	0.0019	CbGeAlD
Methotrexate—ALB—testis—sarcoma	9.31e-05	0.00189	CbGeAlD
Methotrexate—ABCC1—tendon—sarcoma	9.28e-05	0.00188	CbGeAlD
Methotrexate—PGD—lymph node—sarcoma	9.19e-05	0.00186	CbGeAlD
Methotrexate—ABCC4—testis—sarcoma	9.02e-05	0.00183	CbGeAlD
Methotrexate—SLCO1A2—liver—sarcoma	8.86e-05	0.00179	CbGeAlD
Methotrexate—ALB—liver—sarcoma	8.81e-05	0.00178	CbGeAlD
Methotrexate—ABCG2—uterus—sarcoma	8.77e-05	0.00178	CbGeAlD
Methotrexate—ABCC2—testis—sarcoma	8.73e-05	0.00177	CbGeAlD
Methotrexate—SLC16A1—lymph node—sarcoma	8.58e-05	0.00174	CbGeAlD
Methotrexate—ABCC4—liver—sarcoma	8.52e-05	0.00173	CbGeAlD
Methotrexate—ABCC2—liver—sarcoma	8.25e-05	0.00167	CbGeAlD
Methotrexate—AOX1—lymph node—sarcoma	8.1e-05	0.00164	CbGeAlD
Methotrexate—ABCC3—lymph node—sarcoma	7.92e-05	0.0016	CbGeAlD
Methotrexate—ABCC10—lymph node—sarcoma	7.88e-05	0.0016	CbGeAlD
Methotrexate—ABCC1—testis—sarcoma	7.69e-05	0.00156	CbGeAlD
Methotrexate—ABCG2—bone marrow—sarcoma	7.45e-05	0.00151	CbGeAlD
Methotrexate—ABCC1—liver—sarcoma	7.27e-05	0.00147	CbGeAlD
Methotrexate—ALB—lymph node—sarcoma	6.75e-05	0.00137	CbGeAlD
Methotrexate—ABCB1—myometrium—sarcoma	6.67e-05	0.00135	CbGeAlD
Methotrexate—ABCC4—lymph node—sarcoma	6.54e-05	0.00132	CbGeAlD
Methotrexate—ABCB1—embryo—sarcoma	6.42e-05	0.0013	CbGeAlD
Methotrexate—ABCG2—testis—sarcoma	6.36e-05	0.00129	CbGeAlD
Methotrexate—ABCC2—lymph node—sarcoma	6.33e-05	0.00128	CbGeAlD
Methotrexate—ABCB1—seminal vesicle—sarcoma	6.03e-05	0.00122	CbGeAlD
Methotrexate—ABCG2—liver—sarcoma	6.02e-05	0.00122	CbGeAlD
Methotrexate—ABCB1—hematopoietic system—sarcoma	5.73e-05	0.00116	CbGeAlD
Methotrexate—ABCC1—lymph node—sarcoma	5.57e-05	0.00113	CbGeAlD
Methotrexate—Anaphylactic shock—Etoposide—sarcoma	4.98e-05	0.00057	CcSEcCtD
Methotrexate—Mood swings—Doxorubicin—sarcoma	4.98e-05	0.000569	CcSEcCtD
Methotrexate—Asthenia—Thiotepa—sarcoma	4.97e-05	0.000569	CcSEcCtD
Methotrexate—Infection—Etoposide—sarcoma	4.95e-05	0.000566	CcSEcCtD
Methotrexate—Ataxia—Doxorubicin—sarcoma	4.94e-05	0.000565	CcSEcCtD
Methotrexate—Asthenia—Dactinomycin—sarcoma	4.94e-05	0.000565	CcSEcCtD
Methotrexate—Feeling abnormal—Mitoxantrone—sarcoma	4.93e-05	0.000564	CcSEcCtD
Methotrexate—Asthma—Epirubicin—sarcoma	4.91e-05	0.000561	CcSEcCtD
Methotrexate—Pruritus—Thiotepa—sarcoma	4.91e-05	0.000561	CcSEcCtD
Methotrexate—Gastrointestinal pain—Mitoxantrone—sarcoma	4.9e-05	0.00056	CcSEcCtD
Methotrexate—Thrombocytopenia—Etoposide—sarcoma	4.88e-05	0.000558	CcSEcCtD
Methotrexate—Eosinophilia—Epirubicin—sarcoma	4.86e-05	0.000556	CcSEcCtD
Methotrexate—Abdominal pain—Vincristine—sarcoma	4.86e-05	0.000556	CcSEcCtD
Methotrexate—Body temperature increased—Vincristine—sarcoma	4.86e-05	0.000556	CcSEcCtD
Methotrexate—Liver function test abnormal—Doxorubicin—sarcoma	4.85e-05	0.000555	CcSEcCtD
Methotrexate—Skin disorder—Etoposide—sarcoma	4.84e-05	0.000553	CcSEcCtD
Methotrexate—Hyperhidrosis—Etoposide—sarcoma	4.81e-05	0.000551	CcSEcCtD
Methotrexate—Pancreatitis—Epirubicin—sarcoma	4.81e-05	0.00055	CcSEcCtD
Methotrexate—Urticaria—Mitoxantrone—sarcoma	4.76e-05	0.000544	CcSEcCtD
Methotrexate—Breast disorder—Doxorubicin—sarcoma	4.75e-05	0.000543	CcSEcCtD
Methotrexate—Anorexia—Etoposide—sarcoma	4.75e-05	0.000543	CcSEcCtD
Methotrexate—Diarrhoea—Thiotepa—sarcoma	4.74e-05	0.000542	CcSEcCtD
Methotrexate—Body temperature increased—Mitoxantrone—sarcoma	4.73e-05	0.000541	CcSEcCtD
Methotrexate—Abdominal pain—Mitoxantrone—sarcoma	4.73e-05	0.000541	CcSEcCtD
Methotrexate—Toxic epidermal necrolysis—Doxorubicin—sarcoma	4.73e-05	0.000541	CcSEcCtD
Methotrexate—Diarrhoea—Dactinomycin—sarcoma	4.71e-05	0.000538	CcSEcCtD
Methotrexate—Pancytopenia—Epirubicin—sarcoma	4.66e-05	0.000533	CcSEcCtD
Methotrexate—Hypotension—Etoposide—sarcoma	4.65e-05	0.000532	CcSEcCtD
Methotrexate—ABCG2—lymph node—sarcoma	4.61e-05	0.000934	CbGeAlD
Methotrexate—Dysuria—Epirubicin—sarcoma	4.59e-05	0.000525	CcSEcCtD
Methotrexate—Neutropenia—Epirubicin—sarcoma	4.59e-05	0.000525	CcSEcCtD
Methotrexate—Dizziness—Thiotepa—sarcoma	4.59e-05	0.000524	CcSEcCtD
Methotrexate—Upper respiratory tract infection—Epirubicin—sarcoma	4.56e-05	0.000522	CcSEcCtD
Methotrexate—Asthma—Doxorubicin—sarcoma	4.54e-05	0.000519	CcSEcCtD
Methotrexate—Hypersensitivity—Vincristine—sarcoma	4.53e-05	0.000518	CcSEcCtD
Methotrexate—Eosinophilia—Doxorubicin—sarcoma	4.5e-05	0.000514	CcSEcCtD
Methotrexate—Photosensitivity reaction—Epirubicin—sarcoma	4.48e-05	0.000512	CcSEcCtD
Methotrexate—Paraesthesia—Etoposide—sarcoma	4.47e-05	0.000511	CcSEcCtD
Methotrexate—Pancreatitis—Doxorubicin—sarcoma	4.45e-05	0.000509	CcSEcCtD
Methotrexate—Dyspnoea—Etoposide—sarcoma	4.44e-05	0.000508	CcSEcCtD
Methotrexate—Somnolence—Etoposide—sarcoma	4.43e-05	0.000506	CcSEcCtD
Methotrexate—Hypersensitivity—Mitoxantrone—sarcoma	4.41e-05	0.000504	CcSEcCtD
Methotrexate—Asthenia—Vincristine—sarcoma	4.41e-05	0.000504	CcSEcCtD
Methotrexate—Vomiting—Thiotepa—sarcoma	4.41e-05	0.000504	CcSEcCtD
Methotrexate—Pneumonia—Epirubicin—sarcoma	4.4e-05	0.000503	CcSEcCtD
Methotrexate—Drowsiness—Epirubicin—sarcoma	4.38e-05	0.000501	CcSEcCtD
Methotrexate—Infestation—Epirubicin—sarcoma	4.38e-05	0.000501	CcSEcCtD
Methotrexate—Infestation NOS—Epirubicin—sarcoma	4.38e-05	0.000501	CcSEcCtD
Methotrexate—Vomiting—Dactinomycin—sarcoma	4.38e-05	0.0005	CcSEcCtD
Methotrexate—Rash—Thiotepa—sarcoma	4.37e-05	0.0005	CcSEcCtD
Methotrexate—Dermatitis—Thiotepa—sarcoma	4.37e-05	0.000499	CcSEcCtD
Methotrexate—Headache—Thiotepa—sarcoma	4.34e-05	0.000497	CcSEcCtD
Methotrexate—Stevens-Johnson syndrome—Epirubicin—sarcoma	4.34e-05	0.000496	CcSEcCtD
Methotrexate—Rash—Dactinomycin—sarcoma	4.34e-05	0.000496	CcSEcCtD
Methotrexate—Decreased appetite—Etoposide—sarcoma	4.33e-05	0.000495	CcSEcCtD
Methotrexate—ABCB1—uterus—sarcoma	4.33e-05	0.000876	CbGeAlD
Methotrexate—Pancytopenia—Doxorubicin—sarcoma	4.31e-05	0.000493	CcSEcCtD
Methotrexate—Renal failure—Epirubicin—sarcoma	4.3e-05	0.000492	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Etoposide—sarcoma	4.3e-05	0.000492	CcSEcCtD
Methotrexate—Asthenia—Mitoxantrone—sarcoma	4.3e-05	0.000491	CcSEcCtD
Methotrexate—Fatigue—Etoposide—sarcoma	4.29e-05	0.000491	CcSEcCtD
Methotrexate—Stomatitis—Epirubicin—sarcoma	4.27e-05	0.000488	CcSEcCtD
Methotrexate—Pain—Etoposide—sarcoma	4.26e-05	0.000487	CcSEcCtD
Methotrexate—Conjunctivitis—Epirubicin—sarcoma	4.26e-05	0.000487	CcSEcCtD
Methotrexate—Neutropenia—Doxorubicin—sarcoma	4.25e-05	0.000486	CcSEcCtD
Methotrexate—Dysuria—Doxorubicin—sarcoma	4.25e-05	0.000486	CcSEcCtD
Methotrexate—Upper respiratory tract infection—Doxorubicin—sarcoma	4.22e-05	0.000483	CcSEcCtD
Methotrexate—Diarrhoea—Vincristine—sarcoma	4.21e-05	0.000481	CcSEcCtD
Methotrexate—Sweating—Epirubicin—sarcoma	4.2e-05	0.00048	CcSEcCtD
Methotrexate—Haematuria—Epirubicin—sarcoma	4.17e-05	0.000477	CcSEcCtD
Methotrexate—Photosensitivity reaction—Doxorubicin—sarcoma	4.15e-05	0.000474	CcSEcCtD
Methotrexate—Hepatobiliary disease—Epirubicin—sarcoma	4.14e-05	0.000473	CcSEcCtD
Methotrexate—Epistaxis—Epirubicin—sarcoma	4.13e-05	0.000472	CcSEcCtD
Methotrexate—Nausea—Thiotepa—sarcoma	4.12e-05	0.000471	CcSEcCtD
Methotrexate—Feeling abnormal—Etoposide—sarcoma	4.1e-05	0.000469	CcSEcCtD
Methotrexate—Diarrhoea—Mitoxantrone—sarcoma	4.1e-05	0.000468	CcSEcCtD
Methotrexate—Nausea—Dactinomycin—sarcoma	4.09e-05	0.000467	CcSEcCtD
Methotrexate—Agranulocytosis—Epirubicin—sarcoma	4.09e-05	0.000467	CcSEcCtD
Methotrexate—Pneumonia—Doxorubicin—sarcoma	4.07e-05	0.000466	CcSEcCtD
Methotrexate—Gastrointestinal pain—Etoposide—sarcoma	4.07e-05	0.000466	CcSEcCtD
Methotrexate—Dizziness—Vincristine—sarcoma	4.07e-05	0.000465	CcSEcCtD
Methotrexate—Infestation—Doxorubicin—sarcoma	4.05e-05	0.000463	CcSEcCtD
Methotrexate—Drowsiness—Doxorubicin—sarcoma	4.05e-05	0.000463	CcSEcCtD
Methotrexate—Infestation NOS—Doxorubicin—sarcoma	4.05e-05	0.000463	CcSEcCtD
Methotrexate—ABCB1—lymphoid tissue—sarcoma	4.03e-05	0.000816	CbGeAlD
Methotrexate—Stevens-Johnson syndrome—Doxorubicin—sarcoma	4.02e-05	0.000459	CcSEcCtD
Methotrexate—Renal failure—Doxorubicin—sarcoma	3.98e-05	0.000455	CcSEcCtD
Methotrexate—Urticaria—Etoposide—sarcoma	3.96e-05	0.000452	CcSEcCtD
Methotrexate—Haemoglobin—Epirubicin—sarcoma	3.95e-05	0.000452	CcSEcCtD
Methotrexate—Stomatitis—Doxorubicin—sarcoma	3.95e-05	0.000451	CcSEcCtD
Methotrexate—Abdominal pain—Etoposide—sarcoma	3.94e-05	0.00045	CcSEcCtD
Methotrexate—Body temperature increased—Etoposide—sarcoma	3.94e-05	0.00045	CcSEcCtD
Methotrexate—Conjunctivitis—Doxorubicin—sarcoma	3.94e-05	0.00045	CcSEcCtD
Methotrexate—Haemorrhage—Epirubicin—sarcoma	3.93e-05	0.000449	CcSEcCtD
Methotrexate—Hepatitis—Epirubicin—sarcoma	3.93e-05	0.000449	CcSEcCtD
Methotrexate—Vomiting—Vincristine—sarcoma	3.91e-05	0.000447	CcSEcCtD
Methotrexate—Pharyngitis—Epirubicin—sarcoma	3.9e-05	0.000446	CcSEcCtD
Methotrexate—Sweating—Doxorubicin—sarcoma	3.88e-05	0.000444	CcSEcCtD
Methotrexate—Urinary tract disorder—Epirubicin—sarcoma	3.88e-05	0.000444	CcSEcCtD
Methotrexate—Rash—Vincristine—sarcoma	3.88e-05	0.000443	CcSEcCtD
Methotrexate—Dermatitis—Vincristine—sarcoma	3.87e-05	0.000443	CcSEcCtD
Methotrexate—Haematuria—Doxorubicin—sarcoma	3.86e-05	0.000442	CcSEcCtD
Methotrexate—Urethral disorder—Epirubicin—sarcoma	3.85e-05	0.00044	CcSEcCtD
Methotrexate—Headache—Vincristine—sarcoma	3.85e-05	0.00044	CcSEcCtD
Methotrexate—Hepatobiliary disease—Doxorubicin—sarcoma	3.83e-05	0.000438	CcSEcCtD
Methotrexate—Epistaxis—Doxorubicin—sarcoma	3.82e-05	0.000437	CcSEcCtD
Methotrexate—Vomiting—Mitoxantrone—sarcoma	3.81e-05	0.000435	CcSEcCtD
Methotrexate—Visual impairment—Epirubicin—sarcoma	3.79e-05	0.000433	CcSEcCtD
Methotrexate—Agranulocytosis—Doxorubicin—sarcoma	3.78e-05	0.000432	CcSEcCtD
Methotrexate—Rash—Mitoxantrone—sarcoma	3.78e-05	0.000432	CcSEcCtD
Methotrexate—Dermatitis—Mitoxantrone—sarcoma	3.77e-05	0.000431	CcSEcCtD
Methotrexate—Headache—Mitoxantrone—sarcoma	3.75e-05	0.000429	CcSEcCtD
Methotrexate—Erythema multiforme—Epirubicin—sarcoma	3.72e-05	0.000425	CcSEcCtD
Methotrexate—Eye disorder—Epirubicin—sarcoma	3.67e-05	0.00042	CcSEcCtD
Methotrexate—ABCB1—bone marrow—sarcoma	3.67e-05	0.000743	CbGeAlD
Methotrexate—Hypersensitivity—Etoposide—sarcoma	3.67e-05	0.00042	CcSEcCtD
Methotrexate—Tinnitus—Epirubicin—sarcoma	3.66e-05	0.000419	CcSEcCtD
Methotrexate—Haemoglobin—Doxorubicin—sarcoma	3.65e-05	0.000418	CcSEcCtD
Methotrexate—Nausea—Vincristine—sarcoma	3.65e-05	0.000418	CcSEcCtD
Methotrexate—Cardiac disorder—Epirubicin—sarcoma	3.65e-05	0.000417	CcSEcCtD
Methotrexate—Haemorrhage—Doxorubicin—sarcoma	3.64e-05	0.000416	CcSEcCtD
Methotrexate—Hepatitis—Doxorubicin—sarcoma	3.64e-05	0.000416	CcSEcCtD
Methotrexate—Pharyngitis—Doxorubicin—sarcoma	3.61e-05	0.000413	CcSEcCtD
Methotrexate—Urinary tract disorder—Doxorubicin—sarcoma	3.59e-05	0.000411	CcSEcCtD
Methotrexate—Asthenia—Etoposide—sarcoma	3.57e-05	0.000409	CcSEcCtD
Methotrexate—Angiopathy—Epirubicin—sarcoma	3.57e-05	0.000408	CcSEcCtD
Methotrexate—Urethral disorder—Doxorubicin—sarcoma	3.56e-05	0.000408	CcSEcCtD
Methotrexate—Nausea—Mitoxantrone—sarcoma	3.56e-05	0.000407	CcSEcCtD
Methotrexate—Immune system disorder—Epirubicin—sarcoma	3.55e-05	0.000406	CcSEcCtD
Methotrexate—Mediastinal disorder—Epirubicin—sarcoma	3.54e-05	0.000405	CcSEcCtD
Methotrexate—Chills—Epirubicin—sarcoma	3.53e-05	0.000403	CcSEcCtD
Methotrexate—Pruritus—Etoposide—sarcoma	3.52e-05	0.000403	CcSEcCtD
Methotrexate—Visual impairment—Doxorubicin—sarcoma	3.5e-05	0.000401	CcSEcCtD
Methotrexate—Alopecia—Epirubicin—sarcoma	3.47e-05	0.000397	CcSEcCtD
Methotrexate—Mental disorder—Epirubicin—sarcoma	3.44e-05	0.000394	CcSEcCtD
Methotrexate—Erythema multiforme—Doxorubicin—sarcoma	3.44e-05	0.000393	CcSEcCtD
Methotrexate—Erythema—Epirubicin—sarcoma	3.42e-05	0.000391	CcSEcCtD
Methotrexate—Malnutrition—Epirubicin—sarcoma	3.42e-05	0.000391	CcSEcCtD
Methotrexate—Diarrhoea—Etoposide—sarcoma	3.41e-05	0.00039	CcSEcCtD
Methotrexate—Eye disorder—Doxorubicin—sarcoma	3.4e-05	0.000389	CcSEcCtD
Methotrexate—Tinnitus—Doxorubicin—sarcoma	3.39e-05	0.000388	CcSEcCtD
Methotrexate—Cardiac disorder—Doxorubicin—sarcoma	3.37e-05	0.000386	CcSEcCtD
Methotrexate—Dysgeusia—Epirubicin—sarcoma	3.35e-05	0.000383	CcSEcCtD
Methotrexate—Back pain—Epirubicin—sarcoma	3.31e-05	0.000378	CcSEcCtD
Methotrexate—Angiopathy—Doxorubicin—sarcoma	3.3e-05	0.000377	CcSEcCtD
Methotrexate—Dizziness—Etoposide—sarcoma	3.29e-05	0.000377	CcSEcCtD
Methotrexate—Immune system disorder—Doxorubicin—sarcoma	3.28e-05	0.000376	CcSEcCtD
Methotrexate—Mediastinal disorder—Doxorubicin—sarcoma	3.28e-05	0.000375	CcSEcCtD
Methotrexate—Chills—Doxorubicin—sarcoma	3.26e-05	0.000373	CcSEcCtD
Methotrexate—Vision blurred—Epirubicin—sarcoma	3.22e-05	0.000369	CcSEcCtD
Methotrexate—Alopecia—Doxorubicin—sarcoma	3.21e-05	0.000367	CcSEcCtD
Methotrexate—Mental disorder—Doxorubicin—sarcoma	3.19e-05	0.000364	CcSEcCtD
Methotrexate—Ill-defined disorder—Epirubicin—sarcoma	3.17e-05	0.000363	CcSEcCtD
Methotrexate—Vomiting—Etoposide—sarcoma	3.17e-05	0.000362	CcSEcCtD
Methotrexate—Malnutrition—Doxorubicin—sarcoma	3.17e-05	0.000362	CcSEcCtD
Methotrexate—Erythema—Doxorubicin—sarcoma	3.17e-05	0.000362	CcSEcCtD
Methotrexate—Anaemia—Epirubicin—sarcoma	3.16e-05	0.000362	CcSEcCtD
Methotrexate—Rash—Etoposide—sarcoma	3.14e-05	0.000359	CcSEcCtD
Methotrexate—ABCB1—testis—sarcoma	3.14e-05	0.000635	CbGeAlD
Methotrexate—Dermatitis—Etoposide—sarcoma	3.14e-05	0.000359	CcSEcCtD
Methotrexate—Headache—Etoposide—sarcoma	3.12e-05	0.000357	CcSEcCtD
Methotrexate—Dysgeusia—Doxorubicin—sarcoma	3.1e-05	0.000354	CcSEcCtD
Methotrexate—Malaise—Epirubicin—sarcoma	3.08e-05	0.000353	CcSEcCtD
Methotrexate—Vertigo—Epirubicin—sarcoma	3.07e-05	0.000351	CcSEcCtD
Methotrexate—Leukopenia—Epirubicin—sarcoma	3.06e-05	0.00035	CcSEcCtD
Methotrexate—Back pain—Doxorubicin—sarcoma	3.06e-05	0.00035	CcSEcCtD
Methotrexate—Cough—Epirubicin—sarcoma	2.99e-05	0.000341	CcSEcCtD
Methotrexate—Vision blurred—Doxorubicin—sarcoma	2.98e-05	0.000341	CcSEcCtD
Methotrexate—ABCB1—liver—sarcoma	2.97e-05	0.000601	CbGeAlD
Methotrexate—Convulsion—Epirubicin—sarcoma	2.96e-05	0.000339	CcSEcCtD
Methotrexate—Nausea—Etoposide—sarcoma	2.96e-05	0.000338	CcSEcCtD
Methotrexate—Ill-defined disorder—Doxorubicin—sarcoma	2.94e-05	0.000336	CcSEcCtD
Methotrexate—Anaemia—Doxorubicin—sarcoma	2.93e-05	0.000335	CcSEcCtD
Methotrexate—Myalgia—Epirubicin—sarcoma	2.91e-05	0.000333	CcSEcCtD
Methotrexate—Arthralgia—Epirubicin—sarcoma	2.91e-05	0.000333	CcSEcCtD
Methotrexate—Chest pain—Epirubicin—sarcoma	2.91e-05	0.000333	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	2.89e-05	0.000331	CcSEcCtD
Methotrexate—Discomfort—Epirubicin—sarcoma	2.88e-05	0.000329	CcSEcCtD
Methotrexate—Malaise—Doxorubicin—sarcoma	2.85e-05	0.000326	CcSEcCtD
Methotrexate—Vertigo—Doxorubicin—sarcoma	2.84e-05	0.000325	CcSEcCtD
Methotrexate—Leukopenia—Doxorubicin—sarcoma	2.83e-05	0.000324	CcSEcCtD
Methotrexate—Confusional state—Epirubicin—sarcoma	2.82e-05	0.000322	CcSEcCtD
Methotrexate—Anaphylactic shock—Epirubicin—sarcoma	2.79e-05	0.000319	CcSEcCtD
Methotrexate—Infection—Epirubicin—sarcoma	2.77e-05	0.000317	CcSEcCtD
Methotrexate—Cough—Doxorubicin—sarcoma	2.76e-05	0.000316	CcSEcCtD
Methotrexate—Convulsion—Doxorubicin—sarcoma	2.74e-05	0.000314	CcSEcCtD
Methotrexate—Nervous system disorder—Epirubicin—sarcoma	2.74e-05	0.000313	CcSEcCtD
Methotrexate—Thrombocytopenia—Epirubicin—sarcoma	2.73e-05	0.000313	CcSEcCtD
Methotrexate—Skin disorder—Epirubicin—sarcoma	2.71e-05	0.00031	CcSEcCtD
Methotrexate—Hyperhidrosis—Epirubicin—sarcoma	2.7e-05	0.000309	CcSEcCtD
Methotrexate—FPGS—Disease—FOXO1—sarcoma	2.7e-05	0.00111	CbGpPWpGaD
Methotrexate—MTHFR—Disease—TLE1—sarcoma	2.7e-05	0.00111	CbGpPWpGaD
Methotrexate—ABCG2—HIF-1-alpha transcription factor network—VEGFA—sarcoma	2.7e-05	0.00111	CbGpPWpGaD
Methotrexate—Myalgia—Doxorubicin—sarcoma	2.69e-05	0.000308	CcSEcCtD
Methotrexate—Chest pain—Doxorubicin—sarcoma	2.69e-05	0.000308	CcSEcCtD
Methotrexate—Arthralgia—Doxorubicin—sarcoma	2.69e-05	0.000308	CcSEcCtD
Methotrexate—FPGS—Disease—PDGFRB—sarcoma	2.69e-05	0.00111	CbGpPWpGaD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	2.68e-05	0.000306	CcSEcCtD
Methotrexate—PGD—Metabolism—ENO2—sarcoma	2.67e-05	0.0011	CbGpPWpGaD
Methotrexate—Discomfort—Doxorubicin—sarcoma	2.66e-05	0.000304	CcSEcCtD
Methotrexate—Anorexia—Epirubicin—sarcoma	2.66e-05	0.000304	CcSEcCtD
Methotrexate—TYMS—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	2.66e-05	0.0011	CbGpPWpGaD
Methotrexate—PGD—Metabolism—HBA1—sarcoma	2.66e-05	0.0011	CbGpPWpGaD
Methotrexate—FPGS—Disease—PDGFRA—sarcoma	2.65e-05	0.00109	CbGpPWpGaD
Methotrexate—AOX1—Disease—TLE1—sarcoma	2.63e-05	0.00109	CbGpPWpGaD
Methotrexate—Hypotension—Epirubicin—sarcoma	2.61e-05	0.000298	CcSEcCtD
Methotrexate—Confusional state—Doxorubicin—sarcoma	2.6e-05	0.000298	CcSEcCtD
Methotrexate—PGD—Disease—CXCR4—sarcoma	2.6e-05	0.00107	CbGpPWpGaD
Methotrexate—Anaphylactic shock—Doxorubicin—sarcoma	2.58e-05	0.000295	CcSEcCtD
Methotrexate—SLC16A1—Cell surface interactions at the vascular wall—HRAS—sarcoma	2.58e-05	0.00106	CbGpPWpGaD
Methotrexate—Infection—Doxorubicin—sarcoma	2.57e-05	0.000293	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Epirubicin—sarcoma	2.54e-05	0.000291	CcSEcCtD
Methotrexate—Nervous system disorder—Doxorubicin—sarcoma	2.53e-05	0.00029	CcSEcCtD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—sarcoma	2.53e-05	0.00104	CbGpPWpGaD
Methotrexate—Thrombocytopenia—Doxorubicin—sarcoma	2.53e-05	0.000289	CcSEcCtD
Methotrexate—Insomnia—Epirubicin—sarcoma	2.53e-05	0.000289	CcSEcCtD
Methotrexate—Skin disorder—Doxorubicin—sarcoma	2.51e-05	0.000287	CcSEcCtD
Methotrexate—Paraesthesia—Epirubicin—sarcoma	2.51e-05	0.000287	CcSEcCtD
Methotrexate—Hyperhidrosis—Doxorubicin—sarcoma	2.5e-05	0.000286	CcSEcCtD
Methotrexate—ALB—Platelet activation, signaling and aggregation—VEGFC—sarcoma	2.49e-05	0.00103	CbGpPWpGaD
Methotrexate—Dyspnoea—Epirubicin—sarcoma	2.49e-05	0.000285	CcSEcCtD
Methotrexate—Somnolence—Epirubicin—sarcoma	2.48e-05	0.000284	CcSEcCtD
Methotrexate—SLC46A1—Metabolism—PLCG1—sarcoma	2.48e-05	0.00102	CbGpPWpGaD
Methotrexate—Anorexia—Doxorubicin—sarcoma	2.46e-05	0.000282	CcSEcCtD
Methotrexate—Dyspepsia—Epirubicin—sarcoma	2.46e-05	0.000281	CcSEcCtD
Methotrexate—TYMS—Mitotic G1-G1/S phases—MYC—sarcoma	2.45e-05	0.00101	CbGpPWpGaD
Methotrexate—MTHFR—Disease—NPM1—sarcoma	2.43e-05	0.001	CbGpPWpGaD
Methotrexate—Decreased appetite—Epirubicin—sarcoma	2.43e-05	0.000278	CcSEcCtD
Methotrexate—SLC19A1—Disease—KIT—sarcoma	2.42e-05	0.000998	CbGpPWpGaD
Methotrexate—Hypotension—Doxorubicin—sarcoma	2.41e-05	0.000276	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Epirubicin—sarcoma	2.41e-05	0.000276	CcSEcCtD
Methotrexate—Fatigue—Epirubicin—sarcoma	2.41e-05	0.000275	CcSEcCtD
Methotrexate—DHFR—Disease—TLE1—sarcoma	2.4e-05	0.000989	CbGpPWpGaD
Methotrexate—Pain—Epirubicin—sarcoma	2.39e-05	0.000273	CcSEcCtD
Methotrexate—AOX1—Disease—NPM1—sarcoma	2.38e-05	0.000981	CbGpPWpGaD
Methotrexate—Musculoskeletal discomfort—Doxorubicin—sarcoma	2.35e-05	0.000269	CcSEcCtD
Methotrexate—Insomnia—Doxorubicin—sarcoma	2.34e-05	0.000267	CcSEcCtD
Methotrexate—Paraesthesia—Doxorubicin—sarcoma	2.32e-05	0.000265	CcSEcCtD
Methotrexate—ABCB1—HIF-1-alpha transcription factor network—CREB1—sarcoma	2.32e-05	0.000957	CbGpPWpGaD
Methotrexate—TYMS—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	2.32e-05	0.000956	CbGpPWpGaD
Methotrexate—ABCC4—Ectoderm Differentiation—CTNNB1—sarcoma	2.31e-05	0.000955	CbGpPWpGaD
Methotrexate—TYMS—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	2.31e-05	0.000954	CbGpPWpGaD
Methotrexate—Dyspnoea—Doxorubicin—sarcoma	2.3e-05	0.000263	CcSEcCtD
Methotrexate—SLC19A1—Disease—CREB1—sarcoma	2.3e-05	0.00095	CbGpPWpGaD
Methotrexate—Feeling abnormal—Epirubicin—sarcoma	2.3e-05	0.000263	CcSEcCtD
Methotrexate—Somnolence—Doxorubicin—sarcoma	2.3e-05	0.000263	CcSEcCtD
Methotrexate—TYMS—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	2.29e-05	0.000946	CbGpPWpGaD
Methotrexate—Gastrointestinal pain—Epirubicin—sarcoma	2.28e-05	0.000261	CcSEcCtD
Methotrexate—ABCB1—lymph node—sarcoma	2.28e-05	0.000461	CbGeAlD
Methotrexate—Dyspepsia—Doxorubicin—sarcoma	2.27e-05	0.00026	CcSEcCtD
Methotrexate—PGD—Metabolism—PLCG1—sarcoma	2.27e-05	0.000937	CbGpPWpGaD
Methotrexate—Decreased appetite—Doxorubicin—sarcoma	2.25e-05	0.000257	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Doxorubicin—sarcoma	2.23e-05	0.000255	CcSEcCtD
Methotrexate—ABCC4—Hemostasis—PLCG1—sarcoma	2.23e-05	0.00092	CbGpPWpGaD
Methotrexate—Fatigue—Doxorubicin—sarcoma	2.23e-05	0.000255	CcSEcCtD
Methotrexate—Urticaria—Epirubicin—sarcoma	2.22e-05	0.000254	CcSEcCtD
Methotrexate—TYMS—Circadian rythm related genes—JUN—sarcoma	2.22e-05	0.000916	CbGpPWpGaD
Methotrexate—Pain—Doxorubicin—sarcoma	2.21e-05	0.000253	CcSEcCtD
Methotrexate—Abdominal pain—Epirubicin—sarcoma	2.21e-05	0.000252	CcSEcCtD
Methotrexate—Body temperature increased—Epirubicin—sarcoma	2.21e-05	0.000252	CcSEcCtD
Methotrexate—DHFR—Disease—NPM1—sarcoma	2.16e-05	0.000892	CbGpPWpGaD
Methotrexate—Feeling abnormal—Doxorubicin—sarcoma	2.13e-05	0.000243	CcSEcCtD
Methotrexate—Gastrointestinal pain—Doxorubicin—sarcoma	2.11e-05	0.000242	CcSEcCtD
Methotrexate—MTHFR—Disease—ENO2—sarcoma	2.11e-05	0.00087	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—FOXO1—sarcoma	2.1e-05	0.000868	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—PDGFRB—sarcoma	2.1e-05	0.000866	CbGpPWpGaD
Methotrexate—TYMS—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	2.07e-05	0.000856	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—PDGFRA—sarcoma	2.07e-05	0.000853	CbGpPWpGaD
Methotrexate—AOX1—Disease—ENO2—sarcoma	2.06e-05	0.00085	CbGpPWpGaD
Methotrexate—Hypersensitivity—Epirubicin—sarcoma	2.06e-05	0.000235	CcSEcCtD
Methotrexate—FPGS—Disease—KIT—sarcoma	2.06e-05	0.000849	CbGpPWpGaD
Methotrexate—Urticaria—Doxorubicin—sarcoma	2.05e-05	0.000235	CcSEcCtD
Methotrexate—Abdominal pain—Doxorubicin—sarcoma	2.04e-05	0.000234	CcSEcCtD
Methotrexate—Body temperature increased—Doxorubicin—sarcoma	2.04e-05	0.000234	CcSEcCtD
Methotrexate—TYMS—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	2.02e-05	0.000833	CbGpPWpGaD
Methotrexate—Asthenia—Epirubicin—sarcoma	2e-05	0.000229	CcSEcCtD
Methotrexate—Pruritus—Epirubicin—sarcoma	1.98e-05	0.000226	CcSEcCtD
Methotrexate—FPGS—Disease—CREB1—sarcoma	1.96e-05	0.000808	CbGpPWpGaD
Methotrexate—ALB—Folate Metabolism—IL2—sarcoma	1.96e-05	0.000808	CbGpPWpGaD
Methotrexate—PGD—Disease—FOXO1—sarcoma	1.92e-05	0.000794	CbGpPWpGaD
Methotrexate—PGD—Disease—PDGFRB—sarcoma	1.92e-05	0.000792	CbGpPWpGaD
Methotrexate—Diarrhoea—Epirubicin—sarcoma	1.91e-05	0.000218	CcSEcCtD
Methotrexate—SLC19A1—Disease—MDM2—sarcoma	1.9e-05	0.000786	CbGpPWpGaD
Methotrexate—Hypersensitivity—Doxorubicin—sarcoma	1.9e-05	0.000218	CcSEcCtD
Methotrexate—PGD—Disease—PDGFRA—sarcoma	1.89e-05	0.00078	CbGpPWpGaD
Methotrexate—ABCC4—Ectoderm Differentiation—MYC—sarcoma	1.87e-05	0.000774	CbGpPWpGaD
Methotrexate—DHFR—Disease—ENO2—sarcoma	1.87e-05	0.000773	CbGpPWpGaD
Methotrexate—TYMS—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	1.86e-05	0.000767	CbGpPWpGaD
Methotrexate—Asthenia—Doxorubicin—sarcoma	1.85e-05	0.000212	CcSEcCtD
Methotrexate—Dizziness—Epirubicin—sarcoma	1.85e-05	0.000211	CcSEcCtD
Methotrexate—Pruritus—Doxorubicin—sarcoma	1.83e-05	0.000209	CcSEcCtD
Methotrexate—TYMS—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	1.82e-05	0.00075	CbGpPWpGaD
Methotrexate—MTHFR—Disease—PLCG1—sarcoma	1.79e-05	0.000738	CbGpPWpGaD
Methotrexate—Vomiting—Epirubicin—sarcoma	1.78e-05	0.000203	CcSEcCtD
Methotrexate—Diarrhoea—Doxorubicin—sarcoma	1.77e-05	0.000202	CcSEcCtD
Methotrexate—MTHFR—Metabolism—ENO2—sarcoma	1.76e-05	0.000728	CbGpPWpGaD
Methotrexate—Rash—Epirubicin—sarcoma	1.76e-05	0.000201	CcSEcCtD
Methotrexate—Dermatitis—Epirubicin—sarcoma	1.76e-05	0.000201	CcSEcCtD
Methotrexate—MTHFR—Metabolism—HBA1—sarcoma	1.75e-05	0.000724	CbGpPWpGaD
Methotrexate—Headache—Epirubicin—sarcoma	1.75e-05	0.0002	CcSEcCtD
Methotrexate—ALB—Hemostasis—TEK—sarcoma	1.75e-05	0.000722	CbGpPWpGaD
Methotrexate—AOX1—Disease—PLCG1—sarcoma	1.75e-05	0.000721	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—ENO2—sarcoma	1.72e-05	0.000711	CbGpPWpGaD
Methotrexate—MTHFR—Disease—CXCR4—sarcoma	1.72e-05	0.000709	CbGpPWpGaD
Methotrexate—TYMS—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	1.72e-05	0.000708	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—HBA1—sarcoma	1.71e-05	0.000707	CbGpPWpGaD
Methotrexate—Dizziness—Doxorubicin—sarcoma	1.71e-05	0.000195	CcSEcCtD
Methotrexate—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—sarcoma	1.7e-05	0.000702	CbGpPWpGaD
Methotrexate—AOX1—Disease—CXCR4—sarcoma	1.68e-05	0.000693	CbGpPWpGaD
Methotrexate—ABCB1—HIF-1-alpha transcription factor network—JUN—sarcoma	1.67e-05	0.000689	CbGpPWpGaD
Methotrexate—Nausea—Epirubicin—sarcoma	1.66e-05	0.00019	CcSEcCtD
Methotrexate—ABCC4—Platelet activation, signaling and aggregation—IL2—sarcoma	1.64e-05	0.000679	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—CTNNB1—sarcoma	1.64e-05	0.000678	CbGpPWpGaD
Methotrexate—Vomiting—Doxorubicin—sarcoma	1.64e-05	0.000188	CcSEcCtD
Methotrexate—Rash—Doxorubicin—sarcoma	1.63e-05	0.000186	CcSEcCtD
Methotrexate—Dermatitis—Doxorubicin—sarcoma	1.63e-05	0.000186	CcSEcCtD
Methotrexate—FPGS—Disease—MDM2—sarcoma	1.62e-05	0.000668	CbGpPWpGaD
Methotrexate—Headache—Doxorubicin—sarcoma	1.62e-05	0.000185	CcSEcCtD
Methotrexate—SLC46A1—Disease—KIT—sarcoma	1.6e-05	0.000661	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—ANGPT2—sarcoma	1.6e-05	0.00066	CbGpPWpGaD
Methotrexate—DHFR—Disease—PLCG1—sarcoma	1.59e-05	0.000656	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—ENO2—sarcoma	1.57e-05	0.000647	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—HBA1—sarcoma	1.56e-05	0.000643	CbGpPWpGaD
Methotrexate—Nausea—Doxorubicin—sarcoma	1.53e-05	0.000175	CcSEcCtD
Methotrexate—DHFR—Disease—CXCR4—sarcoma	1.53e-05	0.00063	CbGpPWpGaD
Methotrexate—TYMS—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	1.52e-05	0.00063	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—CREB1—sarcoma	1.52e-05	0.000629	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—PLCG1—sarcoma	1.5e-05	0.000618	CbGpPWpGaD
Methotrexate—ABCB1—Allograft Rejection—IL2—sarcoma	1.48e-05	0.000613	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—SRC—sarcoma	1.48e-05	0.000613	CbGpPWpGaD
Methotrexate—PGD—Disease—KIT—sarcoma	1.46e-05	0.000605	CbGpPWpGaD
Methotrexate—TYMS—Circadian rythm related genes—TP53—sarcoma	1.46e-05	0.000604	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—PLCG1—sarcoma	1.46e-05	0.000604	CbGpPWpGaD
Methotrexate—ABCB1—HIF-1-alpha transcription factor network—VEGFA—sarcoma	1.46e-05	0.000602	CbGpPWpGaD
Methotrexate—ABCC4—Platelet activation, signaling and aggregation—SRC—sarcoma	1.44e-05	0.000592	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—NRAS—sarcoma	1.43e-05	0.00059	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—ENO2—sarcoma	1.43e-05	0.00059	CbGpPWpGaD
Methotrexate—ALB—Platelet degranulation—VEGFA—sarcoma	1.43e-05	0.000589	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—HBA1—sarcoma	1.42e-05	0.000586	CbGpPWpGaD
Methotrexate—ABCC4—Platelet activation, signaling and aggregation—VEGFA—sarcoma	1.4e-05	0.000577	CbGpPWpGaD
Methotrexate—FPGS—Disease—CTNNB1—sarcoma	1.4e-05	0.000577	CbGpPWpGaD
Methotrexate—PGD—Disease—CREB1—sarcoma	1.39e-05	0.000576	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—ENO2—sarcoma	1.37e-05	0.000565	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—HBA1—sarcoma	1.36e-05	0.000561	CbGpPWpGaD
Methotrexate—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—sarcoma	1.36e-05	0.000561	CbGpPWpGaD
Methotrexate—ABCC1—Disease—TLE1—sarcoma	1.36e-05	0.00056	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—PDGFRA—sarcoma	1.34e-05	0.000554	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—MYC—sarcoma	1.33e-05	0.000549	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—PLCG1—sarcoma	1.33e-05	0.000549	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle—MDM2—sarcoma	1.32e-05	0.000544	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—EGFR—sarcoma	1.3e-05	0.000537	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle, Mitotic—CCND1—sarcoma	1.28e-05	0.00053	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—VEGFC—sarcoma	1.28e-05	0.00053	CbGpPWpGaD
Methotrexate—MTHFR—Disease—FOXO1—sarcoma	1.27e-05	0.000524	CbGpPWpGaD
Methotrexate—MTHFR—Disease—PDGFRB—sarcoma	1.27e-05	0.000523	CbGpPWpGaD
Methotrexate—FPGS—Disease—SRC—sarcoma	1.26e-05	0.000521	CbGpPWpGaD
Methotrexate—ABCB1—Allograft Rejection—VEGFA—sarcoma	1.26e-05	0.000521	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—MDM2—sarcoma	1.26e-05	0.000521	CbGpPWpGaD
Methotrexate—ALB—Folate Metabolism—TP53—sarcoma	1.26e-05	0.000519	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—ENO2—sarcoma	1.26e-05	0.000518	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—HBA1—sarcoma	1.25e-05	0.000515	CbGpPWpGaD
Methotrexate—MTHFR—Disease—PDGFRA—sarcoma	1.25e-05	0.000515	CbGpPWpGaD
Methotrexate—AOX1—Disease—FOXO1—sarcoma	1.24e-05	0.000511	CbGpPWpGaD
Methotrexate—AOX1—Disease—PDGFRB—sarcoma	1.24e-05	0.000511	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—KRAS—sarcoma	1.23e-05	0.000508	CbGpPWpGaD
Methotrexate—ABCC1—Disease—NPM1—sarcoma	1.22e-05	0.000505	CbGpPWpGaD
Methotrexate—AOX1—Disease—PDGFRA—sarcoma	1.22e-05	0.000503	CbGpPWpGaD
Methotrexate—FPGS—Disease—NRAS—sarcoma	1.21e-05	0.000501	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PLCG1—sarcoma	1.21e-05	0.0005	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PLCG1—sarcoma	1.16e-05	0.000479	CbGpPWpGaD
Methotrexate—PGD—Disease—MDM2—sarcoma	1.15e-05	0.000476	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—MDM2—sarcoma	1.15e-05	0.000475	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle—CCND1—sarcoma	1.15e-05	0.000474	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—IL2—sarcoma	1.14e-05	0.000469	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—ENO2—sarcoma	1.13e-05	0.000468	CbGpPWpGaD
Methotrexate—FPGS—Disease—MYC—sarcoma	1.13e-05	0.000467	CbGpPWpGaD
Methotrexate—DHFR—Disease—FOXO1—sarcoma	1.13e-05	0.000465	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—HBA1—sarcoma	1.13e-05	0.000465	CbGpPWpGaD
Methotrexate—DHFR—Disease—PDGFRB—sarcoma	1.13e-05	0.000465	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle, Mitotic—CCND1—sarcoma	1.12e-05	0.000463	CbGpPWpGaD
Methotrexate—DHFR—Disease—PDGFRA—sarcoma	1.11e-05	0.000457	CbGpPWpGaD
Methotrexate—FPGS—Disease—EGFR—sarcoma	1.11e-05	0.000457	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—CTNNB1—sarcoma	1.09e-05	0.000449	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PLCG1—sarcoma	1.06e-05	0.00044	CbGpPWpGaD
Methotrexate—ABCC1—Disease—ENO2—sarcoma	1.06e-05	0.000437	CbGpPWpGaD
Methotrexate—FPGS—Disease—KRAS—sarcoma	1.05e-05	0.000432	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—HRAS—sarcoma	1.04e-05	0.000431	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle, Mitotic—MYC—sarcoma	1.03e-05	0.000425	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—PLCG1—sarcoma	1.01e-05	0.000416	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—CCND1—sarcoma	1e-05	0.000414	CbGpPWpGaD
Methotrexate—PGD—Disease—CTNNB1—sarcoma	9.95e-06	0.000411	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—SRC—sarcoma	9.92e-06	0.00041	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	9.91e-06	0.000409	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—ENO2—sarcoma	9.86e-06	0.000407	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—SRC—sarcoma	9.83e-06	0.000406	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—HBA1—sarcoma	9.8e-06	0.000405	CbGpPWpGaD
Methotrexate—MTHFR—Disease—KIT—sarcoma	9.66e-06	0.000399	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—VEGFA—sarcoma	9.66e-06	0.000399	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PLCG1—sarcoma	9.61e-06	0.000397	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—NRAS—sarcoma	9.54e-06	0.000394	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—NRAS—sarcoma	9.46e-06	0.000391	CbGpPWpGaD
Methotrexate—AOX1—Disease—KIT—sarcoma	9.44e-06	0.00039	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle—MYC—sarcoma	9.21e-06	0.00038	CbGpPWpGaD
Methotrexate—MTHFR—Disease—CREB1—sarcoma	9.2e-06	0.00038	CbGpPWpGaD
Methotrexate—PGD—Disease—SRC—sarcoma	9e-06	0.000371	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PLCG1—sarcoma	8.99e-06	0.000371	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle, Mitotic—MYC—sarcoma	8.99e-06	0.000371	CbGpPWpGaD
Methotrexate—AOX1—Disease—CREB1—sarcoma	8.99e-06	0.000371	CbGpPWpGaD
Methotrexate—FPGS—Disease—HRAS—sarcoma	8.88e-06	0.000367	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—ENO2—sarcoma	8.87e-06	0.000366	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—HBA1—sarcoma	8.82e-06	0.000364	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—MYC—sarcoma	8.81e-06	0.000364	CbGpPWpGaD
Methotrexate—PGD—Disease—NRAS—sarcoma	8.65e-06	0.000357	CbGpPWpGaD
Methotrexate—ABCC1—Disease—CXCR4—sarcoma	8.64e-06	0.000357	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—EGFR—sarcoma	8.62e-06	0.000356	CbGpPWpGaD
Methotrexate—DHFR—Disease—KIT—sarcoma	8.59e-06	0.000355	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—IL2—sarcoma	8.48e-06	0.00035	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—ENO2—sarcoma	8.43e-06	0.000348	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—HBA1—sarcoma	8.38e-06	0.000346	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PLCG1—sarcoma	8.37e-06	0.000345	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—KRAS—sarcoma	8.21e-06	0.000339	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	8.2e-06	0.000339	CbGpPWpGaD
Methotrexate—DHFR—Disease—CREB1—sarcoma	8.17e-06	0.000337	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—KRAS—sarcoma	8.14e-06	0.000336	CbGpPWpGaD
Methotrexate—PGD—Disease—MYC—sarcoma	8.06e-06	0.000333	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—MYC—sarcoma	8.04e-06	0.000332	CbGpPWpGaD
Methotrexate—PGD—Disease—EGFR—sarcoma	7.88e-06	0.000325	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—ENO2—sarcoma	7.81e-06	0.000322	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—HBA1—sarcoma	7.76e-06	0.00032	CbGpPWpGaD
Methotrexate—MTHFR—Disease—MDM2—sarcoma	7.61e-06	0.000314	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle—TP53—sarcoma	7.56e-06	0.000312	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PLCG1—sarcoma	7.53e-06	0.000311	CbGpPWpGaD
Methotrexate—PGD—Disease—KRAS—sarcoma	7.45e-06	0.000307	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—IL2—sarcoma	7.44e-06	0.000307	CbGpPWpGaD
Methotrexate—AOX1—Disease—MDM2—sarcoma	7.43e-06	0.000307	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—SRC—sarcoma	7.4e-06	0.000305	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—TP53—sarcoma	7.3e-06	0.000301	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—VEGFA—sarcoma	7.2e-06	0.000297	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PLCG1—sarcoma	7.15e-06	0.000295	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	7.14e-06	0.000295	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	7.13e-06	0.000294	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—NRAS—sarcoma	7.12e-06	0.000294	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	7.07e-06	0.000292	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—HRAS—sarcoma	6.98e-06	0.000288	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—HRAS—sarcoma	6.92e-06	0.000286	CbGpPWpGaD
Methotrexate—DHFR—Disease—MDM2—sarcoma	6.76e-06	0.000279	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PLCG1—sarcoma	6.62e-06	0.000274	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—TP53—sarcoma	6.6e-06	0.000273	CbGpPWpGaD
Methotrexate—MTHFR—Disease—CTNNB1—sarcoma	6.57e-06	0.000271	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—SRC—sarcoma	6.49e-06	0.000268	CbGpPWpGaD
Methotrexate—AOX1—Disease—CTNNB1—sarcoma	6.41e-06	0.000265	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	6.39e-06	0.000264	CbGpPWpGaD
Methotrexate—ABCC1—Disease—FOXO1—sarcoma	6.38e-06	0.000263	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PDGFRB—sarcoma	6.37e-06	0.000263	CbGpPWpGaD
Methotrexate—PGD—Disease—HRAS—sarcoma	6.33e-06	0.000261	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—VEGFA—sarcoma	6.32e-06	0.000261	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PDGFRA—sarcoma	6.27e-06	0.000259	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	6.23e-06	0.000257	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—KRAS—sarcoma	6.12e-06	0.000253	CbGpPWpGaD
Methotrexate—MTHFR—Disease—SRC—sarcoma	5.93e-06	0.000245	CbGpPWpGaD
Methotrexate—DHFR—Disease—CTNNB1—sarcoma	5.83e-06	0.000241	CbGpPWpGaD
Methotrexate—AOX1—Disease—SRC—sarcoma	5.8e-06	0.000239	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	5.73e-06	0.000237	CbGpPWpGaD
Methotrexate—MTHFR—Disease—NRAS—sarcoma	5.71e-06	0.000236	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	5.6e-06	0.000231	CbGpPWpGaD
Methotrexate—AOX1—Disease—NRAS—sarcoma	5.58e-06	0.00023	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—TP53—sarcoma	5.44e-06	0.000225	CbGpPWpGaD
Methotrexate—MTHFR—Disease—MYC—sarcoma	5.32e-06	0.00022	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	5.29e-06	0.000219	CbGpPWpGaD
Methotrexate—DHFR—Disease—SRC—sarcoma	5.27e-06	0.000218	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—HRAS—sarcoma	5.21e-06	0.000215	CbGpPWpGaD
Methotrexate—MTHFR—Disease—EGFR—sarcoma	5.2e-06	0.000215	CbGpPWpGaD
Methotrexate—AOX1—Disease—MYC—sarcoma	5.19e-06	0.000214	CbGpPWpGaD
Methotrexate—AOX1—Disease—EGFR—sarcoma	5.08e-06	0.00021	CbGpPWpGaD
Methotrexate—DHFR—Disease—NRAS—sarcoma	5.07e-06	0.000209	CbGpPWpGaD
Methotrexate—MTHFR—Disease—KRAS—sarcoma	4.91e-06	0.000203	CbGpPWpGaD
Methotrexate—ABCC1—Disease—KIT—sarcoma	4.86e-06	0.000201	CbGpPWpGaD
Methotrexate—ALB—Metabolism—ENO2—sarcoma	4.82e-06	0.000199	CbGpPWpGaD
Methotrexate—AOX1—Disease—KRAS—sarcoma	4.8e-06	0.000198	CbGpPWpGaD
Methotrexate—ALB—Metabolism—HBA1—sarcoma	4.79e-06	0.000198	CbGpPWpGaD
Methotrexate—DHFR—Disease—MYC—sarcoma	4.73e-06	0.000195	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	4.71e-06	0.000194	CbGpPWpGaD
Methotrexate—ABCC1—Disease—CREB1—sarcoma	4.63e-06	0.000191	CbGpPWpGaD
Methotrexate—DHFR—Disease—EGFR—sarcoma	4.62e-06	0.000191	CbGpPWpGaD
Methotrexate—DHFR—Disease—KRAS—sarcoma	4.37e-06	0.00018	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—ENO2—sarcoma	4.22e-06	0.000174	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—HBA1—sarcoma	4.19e-06	0.000173	CbGpPWpGaD
Methotrexate—MTHFR—Disease—HRAS—sarcoma	4.18e-06	0.000172	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PLCG1—sarcoma	4.09e-06	0.000169	CbGpPWpGaD
Methotrexate—AOX1—Disease—HRAS—sarcoma	4.08e-06	0.000168	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—IL2—sarcoma	3.84e-06	0.000158	CbGpPWpGaD
Methotrexate—ABCC1—Disease—MDM2—sarcoma	3.83e-06	0.000158	CbGpPWpGaD
Methotrexate—DHFR—Disease—HRAS—sarcoma	3.71e-06	0.000153	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PLCG1—sarcoma	3.58e-06	0.000148	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—SRC—sarcoma	3.35e-06	0.000138	CbGpPWpGaD
Methotrexate—ABCC1—Disease—CTNNB1—sarcoma	3.3e-06	0.000136	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—VEGFA—sarcoma	3.26e-06	0.000135	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—NRAS—sarcoma	3.22e-06	0.000133	CbGpPWpGaD
Methotrexate—ABCC1—Disease—SRC—sarcoma	2.98e-06	0.000123	CbGpPWpGaD
Methotrexate—ABCC1—Disease—NRAS—sarcoma	2.87e-06	0.000119	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—KRAS—sarcoma	2.77e-06	0.000114	CbGpPWpGaD
Methotrexate—ABCC1—Disease—MYC—sarcoma	2.67e-06	0.00011	CbGpPWpGaD
Methotrexate—ABCC1—Disease—EGFR—sarcoma	2.62e-06	0.000108	CbGpPWpGaD
Methotrexate—ABCC1—Disease—KRAS—sarcoma	2.47e-06	0.000102	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—TP53—sarcoma	2.46e-06	0.000102	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—HRAS—sarcoma	2.36e-06	9.73e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—HRAS—sarcoma	2.1e-06	8.67e-05	CbGpPWpGaD
